FDA approves Biogen Idec treatment for hemophilia B
from The Wall Street Journal
The U.S. Food and Drug Administration has approved Biogen Idec Inc. treatment for hemophilia B, a largely inherited disorder that is the second-most common type of hemophilia. The investigational treatment—called Alprolix—won Canadian approval earlier this month. Alprolix is also under review by regulatory authorities in several other markets, including Japan and Australia.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063